SEARCH

SEARCH BY CITATION

References

  • 1
    Davis AM, St-Gallay SA, Kleywegt GJ ( 2008) Limitations and lessons in the use of X-ray structural information in drug design. Drug Disc Today 13: 831841.
  • 2
    Engh RA, Huber R ( 2001) Bond lengths and angles of peptide backbone fragments from structure quality and target parameters. Int Tables Crystallogr.
  • 3
    Touw WG, Vriend G ( 2010) On the complexity of Engh and Huber refinement restraints: the angle tau as example. Acta Cryst D 66: 13411350.
  • 4
    Kleywegt GJ ( 2000) Validation of protein crystal structures. Acta Cryst D 56: 249265.
  • 5
    Zhou Z, Felts AK, Friesner RA, Levy RM ( 2007) Comparative performance of several flexible docking programs and scoring functions: enrichment studies for a diverse set of pharmaceutically relevant targets. J Chem Inf Model 47: 15991608.
  • 6
    Warren GL, Andrews CW, Capelli A, Clarke B, LaLonde J, Lambert MH, Lindvall M, Nevins N, Semus SF, Senger S, Tedesco G, Wall ID, Woolven JM, Peishoff CE, Head MS ( 2006) A critical assessment of docking programs and scoring functions. J Med Chem 49: 59125931.
  • 7
    Whitlow M, Teeter MM ( 1986) An empirical examination of potential-energy minimization using the well-determined structure of the protein crambin. J Am Chem Soc 108: 71637172.
  • 8
    Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM Jr, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA ( 1995) A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 117: 51795197.
  • 9
    McMartin C, Bohacek RS ( 1997) QXP: powerful, rapid computer algorithms for structure-based drug design. J Comput Aided Mol Des 11: 333344.
  • 10
    Ripka AS, Satyshur KA, Bohacek RS, Rich DH ( 2001) Aspartic protease inhibitors designed from computer-generated templates bind as predicted. Org Lett 3: 23092312.
  • 11
    Buchanan JL, Bohacek RS, Luke GP, Hatada M, Lu X, Dalgarno DC, Narula SS, Yuan R, Holt DA ( 1999) Structure-based design and synthesis of a novel class of Src SH2 inhibitors. Bioorg Med Chem Lett 9: 23532358.
  • 12
    Greenspan PD, Clark KL, Tommasi RA, Cowen SD, McQuire LW, Farley DL, van Duzer JH, Goldberg RL, Zhou H, Du Z, Fitt JJ, Coppa DE, Fang Z, Macchia W, Zhu L, Capparelli MP, Goldstein R, Wigg AM, Doughty JR, Bohacek RS, Knap AK ( 2001) Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design. J Med Chem 44: 45244534.
  • 13
    Shakespeare W, Yang M, Bohacek R, Cerasoli F, Stebbins K, Sundaramoorthi R, Azimioara M, Vu C, Pradeepan S, Metcalf C, III, Haraldson C, Merry T, Dalgarno D, Narula S, Hatada M, Lu X, van Schravendijk MR, Adams S, Violette S, Smith J, Guan W, Bartlett C, Herson J, Iuliucci J, Weigele M, Sawyer T ( 2000) Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc Natl Acad Sci USA 97: 93739378.
  • 14
    Ponder JW, Case DA ( 2003) Force fields for protein simulations. Adv Prot Chem 66: 2785.
  • 15
    Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE ( 2000) The Protein Data Bank. Nucleic Acids Res 28: 235242.
  • 16
    Grazulis S, Chateigner D, Downs RT, Yokochi AT, Quirós M, Lutterotti L, Manakova E, Butkus J, Moeck P, Le Bail A ( 2009) Crystallography Open Database—an open-access collection of crystal structures. J Appl Cryst 42: 726729.
  • 17
    Dauter Z, Lamzin V, Wilson KS ( 1995) Proteins at atomic resolution. Curr Opin Struct Biol 5: 784790.